These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27509947)

  • 1. Financial Burden of Cancer Drug Treatment in Lebanon.
    Elias F; Khuri FR; Adib SM; Karam R; Harb H; Awar M; Zalloua P; Ammar W
    Asian Pac J Cancer Prev; 2016; 17(7):3173-7. PubMed ID: 27509947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of Oncology Drugs in the Middle-Eastern Country of Lebanon: An Update (2014-2016).
    Elias F; Bou-Orm IR; Adib SM; Gebran S; Gebran A; Ammar W
    J Glob Oncol; 2018 Sep; 4():1-7. PubMed ID: 30241263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient cancer drug costs: changes, drivers, and the future.
    Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
    Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacy benefit spending on oral chemotherapy drugs.
    Curtiss FR
    J Manag Care Pharm; 2006 Sep; 12(7):570-7. PubMed ID: 16981802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost and burden of cancer in the European Union 1995-2014.
    Jönsson B; Hofmarcher T; Lindgren P; Wilking N
    Eur J Cancer; 2016 Oct; 66():162-70. PubMed ID: 27589247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How state and federal policies as well as advances in genome science contribute to the high cost of cancer drugs.
    Ramsey SD
    Health Aff (Millwood); 2015 Apr; 34(4):571-5. PubMed ID: 25847638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rising cost of anticancer drugs in Australia.
    Karikios DJ; Schofield D; Salkeld G; Mann KP; Trotman J; Stockler MR
    Intern Med J; 2014 May; 44(5):458-63. PubMed ID: 24612257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment of the pharmaceutical expenditure in Hungary].
    Inotai A; Merész G; Kaló Z
    Acta Pharm Hung; 2010; 80(4):162-72. PubMed ID: 21404477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
    Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A roadmap to parity in mental health financing: the case of Lebanon.
    Yehia F; Nahas Z; Saleh S
    J Ment Health Policy Econ; 2014 Sep; 17(3):131-41. PubMed ID: 25543116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Burden of Bladder Cancer Across the European Union.
    Leal J; Luengo-Fernandez R; Sullivan R; Witjes JA
    Eur Urol; 2016 Mar; 69(3):438-47. PubMed ID: 26508308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of cancer across the European Union: a population-based cost analysis.
    Luengo-Fernandez R; Leal J; Gray A; Sullivan R
    Lancet Oncol; 2013 Nov; 14(12):1165-74. PubMed ID: 24131614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tackling Cost: A Prescription for Spending Wisely.
    Tempero M
    J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
    [No Abstract]   [Full Text] [Related]  

  • 16. The economic burden of anemia in cancer patients receiving chemotherapy.
    Lyman GH; Berndt ER; Kallich JD; Erder MH; Crown WH; Long SR; Lee H; Song X; Finkelstein SN
    Value Health; 2005; 8(2):149-56. PubMed ID: 15804323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hong Kong domestic health spending: financial years 1989/90 to 2011/12.
    Tin KY; Tsoi PK; Lee YH; Chong DS; Lam DW; Yeung AY; Ma ES; Maw CK
    Hong Kong Med J; 2015 Jun; 21(3 Suppl 3):1-24. PubMed ID: 26045183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethical and value issues in insurance coverage for cancer treatment.
    Brock DW
    Oncologist; 2010; 15 Suppl 1():36-42. PubMed ID: 20237216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does public insurance provide better financial protection against rising health care costs for families of children with special health care needs?
    Yu H; Dick AW; Szilagyi PG
    Med Care; 2008 Oct; 46(10):1064-70. PubMed ID: 18815528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.